肿瘤生物类似药进入后的使用模式与支付方及患者财务影响
该回顾性队列研究利用2019年7月至2024年12月的商业保险与Medicare数据库,分析贝伐珠单抗、利妥昔单抗和曲妥珠单抗生物类似药进入美国市场后的价格、市场份额及支付方与患者费用变化。仅使用生物类似药的患者月均支付方费用低3820美元,自付费用低39.50美元。
要点
- 生物类似药进入后原研药年均ASP下降3.8%,市场份额年降30%~31.5%。
- 仅用生物类似药者月均支付方费用低3820美元,自付费用低39.50美元。
- 59.4%患者仅用生物类似药,32.5%仅用原研药,6.9%由原研药转换。
核心结论
- 生物类似药进入肿瘤领域与原研药ASP下降及市场份额减少相关,并可能降低支付方成本和患者财务负担。
研究设计与样本
- 根据治疗启动后12个月内使用模式分为四组:仅用生物类似药、仅用原研药、由原研药转换为生物类似药、由生物类似药转换为原研药。
主要发现
- 8710例(59.4%)仅使用生物类似药,4760例(32.5%)仅使用原研药,1015例(6.9%)由原研药转换为生物类似药,170例(1.2%)由生物类似药转换为原研药。
- 生物类似药进入后,3种原研药的平均销售价格(ASP)年均下降3.8%。
- 原研药市场份额在商业保险中每年下降30%,在Medicare Part B市场中每年下降31.5%。
- 与仅使用原研药的患者相比,仅使用生物类似药的患者月均支付方成本低3820美元,月均自付费用低39.50美元。
临床怎么用
- 在临床与支付决策中,可考虑生物类似药作为贝伐珠单抗、利妥昔单抗和曲妥珠单抗的替代选择,以降低支付方与患者费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Biosimilars are highly similar to originator biologics and were introduced to increase market competition, lower the price of biologics, and expand patient access by improving affordability. By the end of 2024, three anticancer biologics have experienced biosimilar entry in the US (bevacizumab, rituximab, and trastuzumab), underscoring the need to evaluate their financial implications for payers and patients. OBJECTIVE: To assess market dynamics and examine financial implications associated with biosimilar use patterns among patients who received bevacizumab, rituximab, or trastuzumab. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort examined price and market share trends and payer and patient costs after biosimilar entry. It used data from the Merative MarketScan commercial database and Medicare database from July 2019 to December 2024. Based on use patterns within 12 months of treatment initiation, patients were categorized into 4 groups: those who exclusively used biosimilars, exclusively used the reference product (ie, originator biologics), switched from the reference product to biosimilars, and switched from biosimilars to the reference product. Data were analyzed between September 2025 and March 2026. MAIN OUTCOMES AND MEASURES: The primary study outcomes were average sales price (ASP), market share of reference products, and mean monthly payer and out-of-pocket costs within the study period. RESULTS: Among 14 655 patients in this study, the mean (SD) age was 57 (13) years, 9985 (68.1%) were female, and the most common cancers were breast cancer (5182 [35.4%]), lymphoma (4320 [29.5%]), and colorectal cancer (1998 [13.6%]). A total of 8710 patients (59.4%) exclusively used biosimilars, 4760 (32.5%) exclusively used the reference product, 1015 (6.9%) switched from the reference product to biosimilars, and 170 (1.2%) switched from biosimilars to the reference product. After biosimilar entry, the ASP of the 3 reference products declined by an average of 3.8% annually. Their market share decreased 30% annually in commercial insurance and 31.5% in the Medicare Part B market. Compared with patients who only used the reference product, those who only used biosimilars rendered a $3820 lower mean monthly payer cost and $39.50 lower mean monthly out-of-pocket cost. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that biosimilar entry was associated with lower ASP and reduced market share for reference biologics in oncology. Market competition introduced by biosimilars was also associated with lowered payer costs and reduced patient financial burden.
引用
- Liu X, Xu X, Lu ZJ, et al. Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients. JAMA Oncol. 2026. PMID: 42658505. doi:10.1001/jamaoncol.2026.3128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。